medsci-skills 4.1.0

package/skills/write-paper/references/journal_profiles/Korean_Journal_of_Internal_Medicine.md

@@ -0,0 +1,178 @@
+# Journal Profile: Korean Journal of Internal Medicine (KJIM)
+
+## Basic Information
+
+- **Publisher:** Korean Association of Internal Medicine
+- **Impact Factor:** [TODO: verify at journal site — typically reported in JCR]
+- **ISSN:** 1226-3303 (print) / 2005-6648 (online)
+- **Frequency:** Bimonthly (January, March, May, July, September, November)
+- **Scope:** All subspecialties of internal medicine — endocrinology, gastroenterology, hematology-oncology, infectious diseases, nephrology, pulmonology, rheumatology, cardiology, geriatrics — with emphasis on Korean and East Asian clinical research
+- **Open Access:** Yes — CC BY-NC reuse policy; PubMed Central indexed
+- **APC (Article Processing Charge):** $1,000 USD (₩1,000,000 KRW) for Original Articles; $300 USD (₩300,000 KRW) for Images of Interest; no charge for Correspondence (effective 2024-10-01)
+- **Language:** English only for manuscripts
+
+---
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | Figures/Tables | References | Authors |
+|------|----------------|----------|----------------|------------|---------|
+| Original Article | No specified maximum | 250 words (structured) | Not specified | Not specified | No limit |
+| Review | 7,500 words (excluding refs/tables/figures) | 200 words (unstructured) | Not specified | Not specified | No limit |
+| Editorial | 2,000 words (excluding refs/tables/figures) | None | Not specified | Not specified | No limit |
+| Images of Interest | 300 words total | None | 2 figures max | Not specified | Max 5 |
+| Correspondence | 500 words (excluding refs) | None | Not specified | 5 references max | No limit |
+
+---
+
+## Abstract Requirements
+
+**Structured abstract** (Original Articles) — 250 words, four required sections:
+
+```
+Background/Aims: [Rationale and primary objective]
+Methods: [Design, population, intervention/exposure, comparator, outcome]
+Results: [Key findings with statistics and 95% CIs]
+Conclusions: [Main interpretation]
+```
+
+**Keywords:** Up to 5 keywords; should refer to Index Medicus Medical Subject Headings (MeSH).
+
+**Unstructured abstract** (Reviews) — 200 words, single paragraph.
+
+---
+
+## Required Sections (Original Article)
+
+1. **Title page**
+2. **Abstract and keywords**
+3. **Introduction**
+4. **Methods**
+5. **Results**
+6. **Discussion**
+7. **Key Message** (KJIM-specific brief take-home statement)
+8. **Acknowledgments**
+9. **References**
+10. **Tables**
+11. **Figure legends**
+
+Note: KJIM requires an explicit "Key Message" section — a brief summary of the clinical implication, similar in spirit to the Key Points format used by other journals.
+
+---
+
+## Ethics Statement
+
+**Human subjects (Korean institutional template):**
+"This study was approved by the Institutional Review Board of [Institution] (approval number: [XXX]); the requirement for informed consent was [waived because of the retrospective nature of the study / obtained from all participants for prospective enrollment]."
+
+**Animal studies:** Approval from Institutional Animal Care and Use Committee (IACUC) required with approval number.
+
+---
+
+## Statistical Reporting
+
+- "Methods of statistical analysis and criteria for statistical significance should be described."
+- p-value format: [TODO: verify at journal site — recommend exact p-values with p < 0.001 below that threshold per ICMJE convention]
+- 95% confidence intervals: [TODO: verify — strongly recommended for primary outcomes per general medical-journal convention]
+- Statistical software and version: [TODO: verify — recommend stating software + version per ICMJE convention]
+
+---
+
+## Figure Requirements
+
+- **Resolution:** 600 DPI (color figures); 1,200 DPI (line art and graphs)
+- **Format:** EPS or TIF preferred; JPEG accepted for color figures
+- **Color:** accepted
+- **Maximum count:** Not specified at the article-type level — use judgment by manuscript type
+
+---
+
+## Common Rejection Reasons
+
+1. **Insufficient clinical relevance for internal medicine readership** — radiology-heavy or imaging-only studies must explicitly translate findings into internal-medicine practice implications
+2. **Single-center study with small N** — multi-center designs or representative national-cohort data preferred for Original Articles
+3. **Missing Key Message** — reviewers check for this section; vague or missing Key Message signals a weak clinical take-home
+4. **Incomplete ethics documentation** — IRB number, approval statement, and informed-consent statement all required
+5. **Poor English language quality** — Korean Association of Internal Medicine expects professionally edited English at submission
+6. **AI use not disclosed in Acknowledgments** — undisclosed AI use is grounds for desk rejection
+
+---
+
+## AI Writing Disclosure Policy
+
+- **Requirement level:** Required (mandatory disclosure)
+- **Permitted scope:** AI may assist in writing; AI cannot be listed as an author
+- **Disclosure location:** Acknowledgments section — must include "specific technical details about the AI model used, including its name, version, source, and the method of application"
+- **AI-generated images:** Not specified on page (recommend following ICMJE / COPE general guidance — avoid AI-generated images or disclose explicitly)
+- **Policy URL:** https://www.kjim.org/authors/authors.php
+
+---
+
+## Cover Letter
+
+Required. Must include:
+- Statement that "neither the submitted material nor portions thereof have been published previously or are under consideration for publication elsewhere"
+- Statement of any potential conflict of interest
+- Brief justification of fit with KJIM scope (internal-medicine clinical relevance)
+
+---
+
+## Open Access and APC
+
+- **CC BY-NC reuse policy** (non-commercial reuse permitted)
+- **APC (effective 2024-10-01):**
+  - Original Article: $1,000 USD (₩1,000,000 KRW)
+  - Images of Interest: $300 USD (₩300,000 KRW)
+  - Correspondence: free
+- PubMed Central indexed (open-access full-text deposit)
+
+---
+
+## Peer Review
+
+- **Type:** Single-blind (reviewer identities anonymized; author identities visible)
+- **Number of reviewers:** Not specified on page
+- **Initial decision turnaround:** Within 4 weeks of receipt (per journal statement)
+
+---
+
+## Author Guidelines URL
+
+https://www.kjim.org/authors/authors.php
+
+---
+
+## Positioning
+
+KJIM is well-suited for:
+- Korean and East Asian internal-medicine clinical research
+- Cross-disciplinary studies that connect imaging or laboratory findings to internal-medicine practice
+- Cohort studies with explicit Korean health-screening or NHIS-based data
+- Smaller single-center observational studies that may not reach radiology-specific or specialty-journal thresholds but have clear internal-medicine relevance
+- Faster initial decision (4 weeks) than many Western general-medicine journals
+
+| Dimension | Korean Journal of Internal Medicine | Yonsei Medical Journal | Journal of Korean Medical Science |
+|-----------|--------------------------------------|------------------------|-----------------------------------|
+| Society | Korean Association of Internal Medicine | Yonsei University College of Medicine | Korean Academy of Medical Sciences |
+| Scope | Internal medicine (general) | All medical specialties | All medical specialties |
+| Korean focus | Strong | Strong | Strong |
+| Open Access | Full OA (CC BY-NC) | Full OA | Full OA |
+| Indexing | PubMed/PMC, Scopus | PubMed/PMC, SCIE, Scopus | PubMed/PMC, SCIE, Scopus |
+| Article emphasis | Internal-medicine clinical research | Cross-disciplinary medical research | Korean medical science (broad) |
+
+---
+
+## Formatting Notes
+
+- References: Vancouver style (numbered, superscripted)
+- Units: SI units
+- Abbreviations: define at first use; avoid excessive abbreviations
+- Korean author names: provide in English; affiliation addresses should include full postal address
+- "Key Message" section is mandatory — do not omit
+
+
+---
+
+## Verification
+- **Source:** https://www.kjim.org/authors/authors.php
+- **Date:** 2026-05-21

package/skills/write-paper/references/journal_profiles/Lancet_Gastroenterology_and_Hepatology.md

@@ -0,0 +1,127 @@
+# Journal Profile: Lancet Gastroenterology & Hepatology
+
+## Journal Identity
+- **Full name:** The Lancet Gastroenterology & Hepatology
+- **Abbreviation:** Lancet Gastroenterol Hepatol
+- **Publisher:** Elsevier (The Lancet Group)
+- **ISSN:** 2468-1253
+- **Frequency:** Monthly
+- **Open Access:** Hybrid (OA optional; APC ~US$5,500 for Gold OA — verify)
+- **Acceptance rate:** ~5–8 % overall (Lancet specialty journals; ~60–70 % desk-rejected before peer review)
+- **Peer review:** Single-blind by ≥ 2 external reviewers + Lancet Group statistical review; portable peer review available across Lancet specialty journals.
+
+## Manuscript Types and Word Limits
+
+Submission guidelines are a near-verbatim shared template across the Lancet Group specialty journals (this profile uses Lancet Diabetes & Endocrinology as the structural reference and adds the LGH-specific non-guideline content below).
+
+| Type | Body Word Limit | Abstract | References | Figures/Tables |
+|------|----------------|----------|------------|----------------|
+| Articles (Original Research) | 3,500–4,500 | 300 words structured | 30 | 5 |
+| Review | 4,000–5,000 | 200 words | 100 | 5 |
+| Series | 5,000–8,000 (commissioned) | per series | per series | per series |
+| Seminar | 5,000–6,000 | 200 words | 80 | 4–5 |
+| Comment | 1,200–1,800 | — | 15 | 1 |
+| Correspondence | 350–500 | — | 5 | — |
+| Clinical Picture | 250 | — | 5 | 1 |
+| Viewpoint / Personal View | 2,000–3,000 | 200 words | 30 | — |
+
+## Abstract Requirements
+**Articles (Original Research):** 300 words, structured under five sub-headings — **Background**, **Methods**, **Findings**, **Interpretation**, **Funding**. Trial registration number on the same page when applicable.
+
+## Required Sections (Article)
+1. **Title page** (≤ 30 words; complete authors + degrees + affiliations; corresponding author; word counts)
+2. **Abstract** (300 words, 5-section structured)
+3. **Research in Context** box (separate from abstract; mandatory at acceptance, recommended at first submission)
+   - Evidence before this study (search strategy + dates)
+   - Added value of this study
+   - Implications of all the available evidence
+4. **Introduction** (concise, no literature review)
+5. **Methods** (sufficient for reproduction; cite reporting guideline + statistical methods; pre-registration / protocol cited)
+6. **Results**
+7. **Discussion** (limit to ~1.5 × abstract length; no separate Conclusions section)
+8. **Contributors** (CRediT taxonomy)
+9. **Declaration of interests**
+10. **Data sharing statement** (mandatory; specifies what data, code, and protocols will be shared and how)
+11. **Acknowledgements**
+12. **References** (Lancet style; ≤ 30 for Articles)
+13. **Tables and Figures** (separate)
+
+## Statistical Reporting
+- Pre-specified primary outcome and analysis plan must be cited (clinical-trial registration, protocol, or pre-print).
+- 95% CI mandatory for primary effect estimates; exact p-values to 2–3 sig figs (p < 0.0001 below threshold).
+- All clinical trials must include CONSORT flow diagram; observational studies STROBE; SR/MA PRISMA; diagnostic accuracy STARD.
+- Statistical software, version, and any custom code disclosed; code must be deposited at acceptance.
+- Sex/gender, race/ethnicity reporting per ICMJE.
+
+## Figures
+- ≤ 5 figures + tables combined for Articles.
+- Lancet figure style enforced (sans-serif, no chartjunk, color-blind safe palette).
+- Resolution ≥ 300 dpi (halftone) / ≥ 1,200 dpi (line art).
+- Figure legends complete at acceptance (caption + abbreviations + statistical details).
+- Forest plot / KM curve / flow diagram / funnel plot — Lancet-house style retouch routinely applied at copy-edit stage.
+
+## Common Rejection Reasons
+1. **Desk reject for scope (60–70 %)** — single-cohort or single-centre studies without explicit international generalizability paragraph.
+2. Missing Research in Context box (returned at revision if not added).
+3. Underpowered or sub-1,000 cohort observational studies (LGH Articles section is dominated by ≥ 10⁴ cohort or multi-centre trials).
+4. Methodology-only papers without a "what changes practice" implications paragraph.
+5. Failure to deposit data + code at acceptance per data-sharing policy.
+6. Discussion exceeding ~1.5 × abstract length (Lancet house style demands brevity).
+7. Cover letter missing data-sharing statement and statement of novelty.
+
+## Cover Letter
+Should include:
+- Confirmation of originality and exclusivity.
+- Explicit "this changes practice/guideline because…" paragraph (Lancet readership demands clinical or policy implication).
+- Data-sharing statement (what / when / where / under what governance).
+- Statement of novelty (1–2 sentences).
+- Suggested 3–5 reviewers from ≥ 2 societies (AASLD / EASL / APASL / KASL recommended for hepatology submissions to ensure international perspective).
+
+## AI Writing Disclosure Policy
+- **Requirement level:** Required (Lancet Group ICMJE-aligned).
+- **Permitted scope:** AI/LLM use disclosed in Methods + cover letter; AI cannot be author; AI-generated images must be declared and reviewed by a human author who takes responsibility.
+- **Disclosure location:** Methods + Cover Letter.
+- **Policy URL:** https://www.thelancet.com/lanchepa/information-for-authors
+
+## Author Guidelines URL
+https://www.thelancet.com/langas/information-for-authors
+
+Submission portal: https://www.editorialmanager.com/thelancet-gh
+Editor email: editor@lancet.com (used for pre-submission inquiries)
+
+## Non-Guideline Editorial Culture (verified from prior submissions, 2024–2025)
+
+### Pre-submission inquiry strongly advised
+- ~60–70 % desk-reject rate. Pre-submission inquiry route: 1-page lay summary + abstract + cover letter + 3 key references + 3-line statement of novelty, emailed to editor@lancet.com.
+- Decisions on inquiries typically arrive within 5–10 working days. Negative inquiry response saves 4–6 weeks vs full submission desk-reject.
+
+### Reviewer pool
+- Substantial overlap with Hepatology (AASLD), Journal of Hepatology (EASL), Hepatology International (APASL), Hepatology Communications, and Liver International. Suggesting reviewers from at least two of those venues is conventional.
+
+### "Changes practice" framing
+- Articles section is curated for evidence that *can change a guideline or clinical pathway*. Methodology-only papers (e.g., comparator-refinement methods) need an explicit "Implications of all the available evidence" paragraph showing how the method, if adopted, will revise existing risk estimates in the literature.
+
+### MASLD natural history precedent
+- Hagström L et al. (Lancet Gastroenterol Hepatol, 2024) is the de-facto reference natural-history systematic review post-2023 nomenclature, and the journal has subsequently been the home venue for MASLD natural-history evidence. Korean health-screening cohort papers fit the line of evidence when the international generalizability claim is explicit.
+
+### Korean-cohort caveat
+- Single-centre Korean cohort studies are accepted, but documented preference for *multi-cohort or international* validation. Cover letter and Discussion should pre-empt the "Asian-only single-centre" reviewer concern by referencing planned external validation (NHANES, UK Biobank, multi-society parallel analysis).
+
+### Practical timing
+- Articles section first decision target ~3 weeks (Lancet promise). Full peer-review cycle to first decision typically 4–6 weeks. Time to acceptance after revision: 2–4 months. Production: ~4–8 weeks to online publication.
+
+## Positioning
+
+**When to submit here.** Large-cohort or multi-centre MASLD natural-history evidence with explicit guideline-revision implications, evidence-synthesis (Cochrane-style or IPD meta-analysis), and methodology contributions that, if adopted, would change how published natural-history rates are interpreted (e.g., comparator-refinement methodology). The journal is a primary destination for evidence the authors believe should change KASL / EASL / AASLD guidance.
+
+**When NOT to submit here.** Single-cohort studies whose contribution is descriptive rather than guideline-changing. Methodology papers without clinical-policy implication. Time-sensitive submissions where ~60 % desk-reject probability is unacceptable.
+
+| Dimension | Lancet GH | Hepatology (AASLD) | J Hepatol (EASL) | Liver International |
+|---|---|---|---|---|
+| Society | Lancet Group / Elsevier | AASLD | EASL | independent (Wiley) |
+| Tier | Q1 (top of GI+Hep specialty) | Q1 | Q1 | Q1 |
+| OA model | Hybrid | Hybrid | Hybrid | Hybrid |
+| Acc. rate (est.) | ~5–8 % | ~10–15 % | ~10–15 % | ~20–25 % |
+| Pre-submission inquiry | Strongly advised | Optional | Optional | Not used |
+| Research in Context box | Mandatory | Optional | Optional | Optional |
+| Ideal cohort size (Articles) | ≥ 10⁴ or multi-centre | ≥ 10³ | ≥ 10³ | ≥ 5×10² |

package/skills/write-paper/references/journal_profiles/Liver_International.md

@@ -0,0 +1,165 @@
+# Journal Profile: Liver International
+
+## Journal Identity
+
+- **Full name**: Liver International
+- **Abbreviation**: Liver Int
+- **Publisher**: John Wiley & Sons
+- **ISSN**: 1478-3223 (print), 1478-3231 (online)
+- **Frequency**: Continuous Publication (no issue pagination; articles published as ready with final citation)
+- **Impact Factor**: [VERIFY at JCR — Q1 hepatology consistent]
+- **Open Access**: Hybrid (standard copyright OR Creative Commons under OA fee; APC applies when OA chosen). >9 published pages = GBP 100/page (excess), unless fully OA.
+- **Acceptance rate**: [VERIFY at journal site]
+- **Peer review**: Single-blind; 2 independent reviewers plus Editors; early rejection without external review permitted; Peer Review Transparency pilot via Publons (opt-out during submission)
+- **Verification date**: 2026-05-21 (against Wiley Liver International Author Guidelines PDF)
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | References | Figures/Tables |
+|------|----------------|----------|------------|----------------|
+| Original Article | 5,000 (incl. title page, abstract, lay summary, main text; excl. refs/figs/tables/legends) | 250 words **structured** (Background & Aims, Methods, Results, Conclusions) | 50 | 8 (max 6 panels each) |
+| Systematic Review / Meta-Analysis | 6,000 (incl. title page, abstract, key points, main text; excl. refs/figs/tables) | 250 **structured** (same headings as Original) | 50 | 4 (Key Points box mandatory, ≤5 bullets ≤100w) |
+| Brief Definitive Report | 3,000 (incl. title page, abstract, main text, refs) | 150 unstructured | 20 | 2 |
+| Review Article | 5,000 recommended / 6,000 upper limit (incl. title page, abstract, key points, main text; excl. refs/figs/tables) | 250 unstructured | 150 | Tables/figures encouraged; **Key Points box mandatory** (≤5 bullets ≤100w) |
+| Mini-Review | 4,000 (incl. title page, unstructured abstract, key points, main text; excl. refs/fig legends/tables) | 250 unstructured | 30 | 2 (Key Points box mandatory ≤5 bullets ≤100w) |
+| Research Letter | 1,500 | None | 10 | 2 (max 10 authors) |
+| Editorial | 1,500 | None | 20 | 1 (highly recommended) |
+| Letter to the Editor | 400 (main text only; about a paper published in Liver Int within 6 months) | None | 5 | 1 (max 4 authors; case reports auto-rejected) |
+| Liver International Images | 250 (short description) | — | 5 | — (max 4 authors) |
+
+**Lay Summary**: 2–3 sentences in plain English, mandatory on revised manuscripts (encouraged at initial submission) for Original Articles.
+
+**Key Points box**: max 5 bullet points, ≤100 words total — mandatory for Systematic Reviews / Meta-Analyses and Review Articles.
+
+---
+
+## Abstract Requirements
+
+Original Article: 250 words, **structured**:
+
+```
+Background & Aims:
+Methods:
+Results:
+Conclusions:
+```
+
+No abbreviations, footnotes, or references in abstract. Electronic word count must be provided at the end of the abstract.
+
+---
+
+## Required Sections (Original Article)
+
+Main text file order:
+
+1. **Title** (max 130 characters, no abbreviations)
+2. **Full names of all authors**
+3. **Institutional affiliations** (superscript numerals, footnote for author changes)
+4. **Keywords**
+5. **Abstract** (structured, 250 words)
+6. **Lay Summary** (2–3 sentences plain English; mandatory on revision)
+7. **Introduction**
+8. **Methods**
+9. **Results**
+10. **Discussion**
+11. **Acknowledgments**
+12. **Conflict of Interest Statement**
+13. **Funding** (title page)
+14. **References**
+15. **Tables** (each with title and footnotes; max 10 columns; portrait orientation)
+16. **Figure legends**
+17. **Appendices** (if any, separate files)
+
+**Reporting-guideline compliance is enforced**:
+- Observational studies: STROBE
+- Systematic reviews / MA: PRISMA (checklist required as supplement; failure → automatic rejection)
+- Diagnostic / prognostic: STARD
+- RCTs: [TODO: verify CONSORT expectation]
+- Animal: ARRIVE
+- Qualitative: SRQR
+- Quality improvement: SQUIRE
+- Economic: CHEERS
+- Study protocols: SPIRIT
+- Practice guidelines: AGREE
+
+Clinical trial registration is **mandatory** — unregistered trials are not accepted. Trial register name and registration number must appear at the end of the abstract.
+
+---
+
+## Statistical Reporting
+
+- Statistical measures (SD, SEM) must be identified in table headings
+- Footnote symbols in tables: †, ‡, §, ¶ (in that order); *, **, *** reserved for P-values
+- Descriptive research or methodology papers without clinical/translational relevance are not considered — statistical analyses must serve a clinical or mechanistic question
+- P-value format not explicitly specified in AGL; default convention applies — report exact P-values to 2–3 significant figures; use P<0.001 below that threshold; 95% CI for primary outcomes; state statistical software and version
+
+---
+
+## Figures
+
+- **Maximum**: 8 figures/tables combined (Original Article); max 6 panels per figure
+- **Resolution**: .eps at minimum 800 dpi (graphs/charts) OR .tiff at minimum 300 dpi (photographs / mixed)
+- **Orientation**: portrait, actual print size
+- **Column widths**: 8.5 cm (one column) or 17.5 cm (two columns); height up to 23.5 cm
+- **Color**: permitted; separate files for multi-part figures
+- **Tables**: portrait orientation only; must be editable files (not JPG/TIFF); max 10 columns
+
+---
+
+## Common Rejection Reasons
+
+1. Purely descriptive research or methodology papers without clinical/translational significance (explicit journal statement — grounds for auto-rejection)
+2. Missing or retrospective clinical trial registration
+3. Missing PRISMA checklist for systematic reviews / meta-analyses (auto-rejection)
+4. Case reports (explicitly not accepted; rejected without review)
+5. Poor English quality (Editors reserve right to reject on language grounds alone)
+6. Authorship irregularities not meeting ICMJE 4-criteria
+7. Exceeding word / reference / figure limits
+8. Missing lay summary on revision
+
+---
+
+## Cover Letter
+
+Cover letter is **required** with all submissions. Should include:
+- Strengths of the manuscript (short positioning)
+- Any commercial relationships (consultancies, patent-licensing) that might pose conflict of interest — with full details of the entity, address, and financial disclosure when applicable
+- Statement that the manuscript is not published or under consideration elsewhere
+- Corresponding author contact information with ORCID iD
+
+---
+
+## AI Writing Disclosure Policy
+
+- **Requirement level:** Required — Liver International follows Wiley's AI policy, which implements ICMJE guidance (the Author Guidelines PDF does not contain a dedicated AI section; publisher-wide policy applies)
+- **Permitted scope:** Disclosure of all generative AI and AI-assisted technologies used in manuscript preparation. AI tools cannot be listed as authors. Basic grammar/spelling/reference tools are exempt.
+- **Disclosure location:** **Methods** (if AI was used in study/data-analysis pipeline) or **Acknowledgements** (if AI was used in drafting/editing). Specify software name, version, developer, and scope of use. (Wiley publisher-wide ICMJE policy applies; AGL itself silent on AI specifics.)
+- **AI-generated images:** Not specified in the journal's author guidelines; Wiley publisher policy applies (treat as restricted unless explicit permission obtained).
+- **Policy URL:** https://authors.wiley.com/author-resources/Journal-Authors/open-access/ethics/index.html (Wiley publisher-wide; redirected from authorservices.wiley.com per 2026-05-21 fetch)
+
+---
+
+## Author Guidelines URL
+
+https://onlinelibrary.wiley.com/page/journal/14783231/homepage/forauthors.html
+
+Submission: https://authors.wiley.com/journal/LIV (Research Exchange) or https://mc.manuscriptcentral.com/liverint (ScholarOne)
+Editorial Office: LIVeditorialoffice@wiley.com
+
+---
+
+## Positioning
+
+**When to submit here.** International hepatology cohort studies with clinical or translational significance, MASLD/NAFLD natural history, HCC prognostication, novel biomarkers with clinical validation, liver transplantation outcomes. Strong fit for Asian/European/American multi-center studies. Explicit preference for clinical relevance over purely descriptive epidemiology.
+
+**When NOT to submit here.** Purely descriptive or methodology-only papers; case reports (auto-rejected); basic science without translational relevance; unregistered clinical trials; papers without clear clinical question.
+
+| Dimension | Liver International | Clinical and Molecular Hepatology | Journal of Hepatology (EASL) | Alimentary Pharmacology & Therapeutics |
+|-----------|--------------------|----------------------------------|------------------------------|----------------------------------------|
+| Society | Wiley (independent) | KASL (Korean) | EASL (European) | Wiley (independent) |
+| Scope | Clinical + experimental hepatology, international | Basic + clinical hepatology, Korean/Asian focus | Mechanistic + guideline-defining | GI/hepatology therapeutics |
+| Impact factor | [verify JCR] | [verify JCR] | [verify JCR] | [verify JCR] |
+| Emphasis | Clinical utility, translational, multi-disciplinary | Korean/Asian epidemiology, KASL alignment | High-impact mechanistic | Therapeutics, observational drug safety |
+| OA model | Hybrid | Full OA | Hybrid | Hybrid |
+| Methodology-only papers | Rejected | Case-by-case | Rejected | Rejected |
+| Case reports | Rejected | Not mentioned | Rejected | Rejected |

package/skills/write-paper/references/journal_profiles/Medical_Image_Analysis.md

@@ -0,0 +1,147 @@
+# Journal Profile: Medical Image Analysis (MedIA)
+
+## Journal Identity
+
+- **Full name**: Medical Image Analysis
+- **Abbreviation**: Med Image Anal
+- **Publisher**: Elsevier
+- **ISSN**: 1361-8415 (print), 1361-8423 (online)
+- **Frequency**: 8 issues/year
+- **Impact Factor**: ~10.9 (JCR 2023), top-ranked in medical image computing
+- **Open Access**: Hybrid (optional OA; Elsevier transformative agreements may apply)
+- **Acceptance rate**: ~20%
+- **Peer review**: Single-blind; associate editors with strong technical backgrounds
+
+## Manuscript Types and Word Limits
+
+| Type | Body Word Limit | Abstract | References | Figures |
+|------|----------------|----------|------------|---------|
+| Original Article | No strict limit (typically 8000-12000) | 200 words | No strict limit | No strict limit |
+| Short Communication | 4000 words | 150 words | 30 | 6 |
+| Review Article | No strict limit | 200 words | No strict limit | No strict limit |
+| Position Paper | No strict limit | 200 words | No strict limit | No strict limit |
+
+**Note**: MedIA is methods-focused with no strict word or figure limits for full articles. Papers are typically longer than clinical journals (8000-12000 words common). Quality and completeness are prioritized over brevity.
+
+---
+
+## Abstract Requirements
+
+**Unstructured abstract, 200 words maximum:**
+
+A single paragraph covering:
+- Problem and clinical motivation (1-2 sentences)
+- Proposed method or approach (2-3 sentences)
+- Key experimental results with quantitative metrics (2-3 sentences)
+- Significance or conclusion (1 sentence)
+
+---
+
+## Required Sections (Original Article)
+
+1. **Introduction** — thorough literature review expected (longer than clinical journals); clear statement of contribution at end
+2. **Related Work** (optional but common) — detailed comparison with prior methods
+3. **Methods**
+   - Mathematical formulation
+   - Model architecture with diagrams
+   - Training details: optimizer, learning rate, batch size, epochs, augmentation
+   - Loss function
+   - Implementation details
+4. **Experiments**
+   - Datasets: detailed description with statistics (patients, images, annotations)
+   - Evaluation metrics: standard metrics for the task (Dice, AUC, FROC, etc.)
+   - Comparison with state-of-the-art methods
+   - Ablation study: systematic evaluation of each component's contribution
+   - Cross-validation or train/val/test split details
+5. **Results** — tables and figures with quantitative comparisons
+6. **Discussion** — clinical relevance, limitations, failure cases
+7. **Conclusion**
+
+---
+
+## Statistical Reporting
+
+MedIA follows technical computing conventions rather than clinical statistical standards:
+- Report all metrics with standard deviation or 95% CI across folds/runs.
+- For segmentation: Dice coefficient, Hausdorff distance (95th percentile preferred), average surface distance.
+- For detection: sensitivity, false positives per scan (FROC), precision-recall.
+- For classification: AUC, sensitivity, specificity, accuracy, F1-score.
+- Statistical significance testing between methods: paired tests (Wilcoxon signed-rank, paired t-test, DeLong for AUC comparison).
+- Report results across multiple random seeds if stochastic training is involved.
+- Effect of hyperparameter choices should be evaluated (sensitivity analysis or ablation).
+- Computational cost: report training time, inference time per image/volume, GPU memory.
+- Software framework and version (PyTorch, TensorFlow) must be identified.
+
+---
+
+## Figures
+
+- **No strict figure limit** — use as many as needed for clarity
+- **Required figure types**: model architecture diagram, qualitative result examples (success and failure cases), quantitative comparison tables/charts
+- **Resolution**: 300 DPI (vector preferred for diagrams)
+- **Format**: PDF, EPS, TIFF
+- **Color**: Free, encouraged
+- **LaTeX**: Manuscripts in LaTeX are common and well-supported; use Elsevier article class
+
+---
+
+## Manuscript Format
+
+- **LaTeX strongly preferred** — use `elsarticle.cls` document class
+- **Microsoft Word** also accepted but less common
+- **Line numbering**: Required for review
+- **Supplementary material**: Unlimited; common for additional experiments, video demonstrations
+- **Code**: Strongly encouraged to share via GitHub; mention in Data/Code Availability statement
+
+---
+
+## Common Rejection Reasons
+
+1. **Insufficient technical novelty** — MedIA expects novel methodology; applying existing methods to new datasets without methodological contribution is insufficient
+2. **No comparison with state-of-the-art** — must compare against recent competitive methods on same datasets
+3. **Missing ablation study** — each proposed component must be justified experimentally
+4. **Single dataset evaluation** — multi-dataset evaluation strongly preferred for generalizability claims
+5. **No failure case analysis** — reviewers expect honest discussion of when the method fails
+6. **Poor reproducibility** — missing implementation details, no code availability
+7. **Weak clinical motivation** — pure technical novelty without medical relevance may be redirected to computer vision venues
+8. **Unfair comparisons** — different training data, augmentation, or post-processing between proposed and baseline methods
+
+---
+
+## Cover Letter
+
+Should emphasize:
+- Technical contribution (novel method, not just novel application)
+- Clinical relevance and potential impact
+- Reproducibility (code/data availability plans)
+- Suggested reviewers with relevant expertise (3-5 recommended)
+
+---
+
+## Author Guidelines URL
+
+https://www.elsevier.com/journals/medical-image-analysis/1361-8415/guide-for-authors
+
+---
+
+## Positioning
+
+Medical Image Analysis is appropriate when:
+- Novel computational method for medical image analysis with rigorous evaluation
+- Comprehensive benchmark study establishing new baselines
+- Methodological innovation (new architecture, training strategy, representation) validated on medical data
+- Multi-dataset evaluation with ablation demonstrating each component's contribution
+
+Not appropriate for: clinical validation studies without methodological contribution (use clinical journals), application of off-the-shelf models without modification (use application-specific journals), pure computer vision without medical data (use CVPR/MICCAI proceedings).
+
+---
+
+## Differentiation from Related Venues
+
+| Dimension | MedIA | IEEE TMI | MICCAI |
+|-----------|-------|---------|--------|
+| Format | Journal (long) | Journal (short, page limit) | Conference proceedings |
+| Review cycle | 3-6 months | 3-6 months | Annual deadline |
+| Length | 8000-12000 words | 10-12 pages (IEEE 2-col) | 8-10 pages |
+| Emphasis | Method depth + ablation | Broader scope, shorter papers | Novelty + preliminary results |
+| Impact factor | ~10.9 | ~10.6 | N/A (proceedings) |